论文部分内容阅读
目的观察吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒性反应。方法38例Ⅲ～Ⅳ期NSCLC患者均经病理组织学或细胞学检查确诊。治疗剂量国产吉西他滨(泽菲)1000mg/m2,静滴,第1,8天,每3～4周重复,2周期后CT评价疗效。结果38例患者均可评价,获得CR0例,PR10例,有效率26.3%(10/38)。中位疾病进展时间(TTP)为6.1个月,中位生存期6.9个月,1年生存率27.2%。主要的毒副反应为白细胞及血小板降低,均可耐受。结论吉西他滨单药治疗老年晚期NSCLC疗效确切,可明显改善患者生存质量,延长生存时间,副反应轻,顺应性好。
Objective To observe the clinical efficacy and toxicity of gemcitabine in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 38 cases of stage Ⅲ ~ Ⅳ NSCLC patients were diagnosed by pathological or cytological examination. Therapeutic dose of domestic gemcitabine (Zephyve) 1000mg / m2, intravenous infusion, the first 1,8 days, repeated every 3 to 4 weeks, 2 weeks after the CT evaluation of efficacy. Results 38 patients were evaluable, CR0 cases, PR10 cases, the effective rate was 26.3% (10/38). The median time to progression (TTP) was 6.1 months, median survival 6.9 months, and 1-year survival 27.2%. The main side effects of leukopenia and thrombocytopenia can be tolerated. Conclusion Gemcitabine monotherapy for the treatment of elderly patients with advanced NSCLC is effective, which can significantly improve the quality of life of patients, prolong the survival time, mild side effects, and good compliance.